NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing oncology outcomes through the development of next-generation bifunctional antibodies.

 

NAYA has developed a versatile plug and play bifunctional antibody construct that promotes avidity and a synapse effect, significantly enhancing precision tumor killing.

 

Our two priority development franchises are Hepatocellular Carcinoma (HCC) and Multiple Myeloma, with an expanding portfolio of assets currently including:

 

NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of HCC, with a unique mechanism of action targeting non-responders to the current immunotherapy standard of care, cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025.

 

NY-500, an AI-optimized PD-1 x VEGF bifunctional antibody aiming to be the first PD-1 x VEGF to market in HCC, with translational clinical and preclinical data in 2025 and Phase I/II in HCC to be initiated in early 2026.

 

NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma with a unique mechanism of action enhancing safety and efficacy and a differentiated profile to daratumumab and T-cell engagers, aiming to enroll patients in its Phase I/II clinical trials in early 2026.

 

Our data has been presented at major oncology meetings including the American Society of Hematology (ASH), The American Association of Cancer Research (AACR), The Society for Immunotherapy of Cancer (SITC), and the European Society for Medical Oncology (ESMO).

 

Clinical development has been designed by our scientific advisory board of leading liver cancer and multiple myeloma experts to allow for early inflection points and accelerated development based on early data.